Bentzenhendrix3725

Since December 2016, the basic military training (BMT) facility for the Canadian Armed Forces (CAF) has experienced repeated outbreaks of Group A

(GAS). In 2018, a voluntary mass antibiotic prophylaxis (MAP) program was implemented to interrupt GAS transmission among recruits. The objective of this study was to describe the epidemiology of three GAS outbreaks and a period of increased pharyngitis infections at the CAF BMT facility in Québec over a two-year span, and to detail the prevention and control measures implemented to mitigate the risk to recruit health.

Descriptive data were collected on invasive and severe GAS cases along with laboratory data including genotyping of throat swabs from recruits presenting with pharyngitis. A laboratory-based acute respiratory infection surveillance system was used to aid in monitoring and decision-making. Close contacts of recruits were assessed for asymptomatic GAS carriage and MAP adverse events surveillance was conducted.

Three distinct GAS outbreaks occurred at the Canadian Forces Leadership and Recruit School totaling eight invasive (iGAS) and 13 severe (sGAS) cases over two years. All iGAS/sGAS cases, apart from one instructor, were among recruits. The predominant strain in all three outbreaks was type

. A total of 11,293 recruits received MAP (penicillin G benzathine or azithromycin) between March 7, 2018 and November 18, 2019. There were eight reported serious adverse events related to penicillin administration.

The CAF BMT facility experienced three GAS outbreaks over the course of two years, and despite the use of enhanced hygiene measures, only MAP has been effective in quelling these outbreaks.

The CAF BMT facility experienced three GAS outbreaks over the course of two years, and despite the use of enhanced hygiene measures, only MAP has been effective in quelling these outbreaks.[This corrects the article DOI 10.1002/advs.202001845.].

Between December 2016 and March 2018, two outbreaks of Group A

(GAS) infection occurred at the Canadian Forces Leadership and Recruit School. A voluntary mass antibiotic prophylaxis (MAP) program was implemented in March 2018, to interrupt an ongoing GAS outbreak, and to prevent future outbreaks.

Instructors and recruits were offered a one-time intramuscular injection of 1.2 million units penicillin G benzathine (PGB). Individuals with a penicillin allergy were offered azithromycin; 500 mg orally once weekly for four consecutive weeks. Instructors and recruits were also asked to complete a voluntary and anonymous survey one week after receipt of MAP, to detect MAP-related adverse events.

MAP was offered to 2,749 individuals; 2,707 of whom agreed to receive it (98.5% uptake). The majority of personnel experienced adverse events in the days following MAP; 92.3% of personnel who received PGB reported localized pain at the injection site, and 70.2% of personnel who received azithromycin reported gastrointestinal symptoms. However, only five cases of serious adverse events were reported, and less than 1% of recruits could not complete their basic military training course because of MAP-related adverse events.

The MAP program implemented in March 2018 was the first of its kind in the Canadian Armed Forces, and the largest single use of PGB in a defined group in Canada. It resulted in very few serious adverse events and with minimal impact on military recruits' successful completion of recruit training.

The MAP program implemented in March 2018 was the first of its kind in the Canadian Armed Forces, and the largest single use of PGB in a defined group in Canada. It resulted in very few serious adverse events and with minimal impact on military recruits' successful completion of recruit training.

Annual influenza vaccination is recommended for all individuals six months of age and older, including those with HIV infection. Prior to this statement, the National Advisory Committee on Immunization (NACI) stated that live attenuated influenza vaccine (LAIV) was contraindicated for all individuals with HIV infection. The objective of this article is to update NACI's guidance on the use of LAIV for HIV-infected individuals.

A systematic literature review of the use of LAIV in individuals with HIV was undertaken. The Canadian Adverse Events Following Immunization Surveillance System was searched for reports of adverse events following vaccination with LAIV in HIV-infected individuals. NACI approved the revised recommendations.

NACI concluded that LAIV is immunogenic in children with HIV, and available data suggest that it is safe, although data were insufficient to detect possible uncommon adverse effects. LAIV may be considered as an option for vaccination of children 2-17 years old who meet the following criteria 1) receiving highly active antiretroviral therapy for at least four months; 2) CD4 count of 500/µL or greater if age 2-5 years, or of 200/µL or greater if age 6-17 years; and 3) HIV plasma RNA less than 10,000 copies/mL. LAIV remains contraindicated for adults with HIV because of insufficient data. Intramuscular influenza vaccination is considered the standard for children living with HIV by NACI and the Canadian Paediatric & Perinatal HIV/AIDS Research Group, particularly for those without HIV viral load suppression (i.e. plasma HIV RNA is 40 copies/mL or greater). However, if intramuscular (IM) vaccination is not accepted by the patient or substitute decision-maker, LAIV would be reasonable for children meeting the criteria listed above.

LAIV may be considered as an option for annual vaccination of selected children with HIV.

LAIV may be considered as an option for annual vaccination of selected children with HIV.

Nucleic acid amplification testing (NAAT) was validated in Ontario in 2018 to test for chlamydia and gonorrhea at extragenital (pharyngeal, rectal) sites. Prior to this validation, extragenital testing could be done only by culture in Ontario. The objective of this study was to determine the number and proportion of gonorrhea and chlamydia cases that were detected exclusively through extragenital (pharyngeal and/or rectal) testing after the implementation of extragenital NAAT for these two infections at Sexual Health Clinic among gay, bisexual, and other men who have sex with men (gbMSM).

Case and laboratory data from before and after NAAT implementation were used to compare the rates of diagnosis of gonorrhea and chlamydia among gbMSM who presented at Sexual Health Clinics and the percent increase in diagnoses in gbMSM in the entire population.

Among gbMSM seen at the clinic after implementation of NAAT testing, 70% of gonorrhea cases and 65% of chlamydia cases were detected exclusively at extragenital sites, corresponding to a four and two-fold increase, respectively, in the average annual number of cases diagnosed. Futibatinib supplier As well, although approximately 50% more pharyngeal than rectal testing occurred, a higher proportion of chlamydia cases were detected rectally than would have been expected; this was not the case for gonorrhea, where most infections were pharyngeal.

It is important that clinicians perform extragenital testing among gbMSM who have sexual contact involving extragenital sites with more than one partner.

It is important that clinicians perform extragenital testing among gbMSM who have sexual contact involving extragenital sites with more than one partner.Within the Canadian Armed Forces (CAF), public health is managed by the Directorate of Force Health Protection (DFHP), a branch of the Canadian Forces Health Services Group. Since the emergence of the novel coronavirus (SARS-CoV-19), DFHP has become heavily involved in health surveillance, outbreak monitoring, policy development, providing evidence-based guidance and advice, liaising with other national, provincial and territorial, municipal and international public health agencies, and ensuring environmental safety of CAF members. Some specific activities include supporting operations and deployments, amending policies and training and promoting hand hygiene, physical distancing and personal protective equipment use. In addition to taking measures to protect its members, CAF-Department of National Defence has contributed to Canada's national response to coronavirus disease 2019 (COVID-19). The DFHP will be developing training for allied health professionals to assist with contact tracing and follow-up, and will ensure adequate resources are in place to manage surge capacity for COVID-19. With these ongoing efforts, initiatives and lessons learned, DFHP is well placed to carry on with its mandate to protect and promote the health and well-being of CAF members and National Defence civilian employees, assisting Canadians and ensuring that CAF members are ready to serve their missions at home and abroad.Vaccines are among the safest therapeutic agents, and serious adverse events rarely occur. link2 When they do occur, an individual may have to bear some or all of the costs associated with their injuries, seek compensation through litigation or, if available, seek compensation from a publicly-supported Vaccine Injury Compensation Program (VIC Programs). link3 The VIC Programs are "no-fault" compensation schemes in which governments compensate individuals who are harmed by properly manufactured vaccines. There are ethical, legal and practical rationales to support these programs. Worldwide there are 19 countries that have implemented VIC Programs; in the majority of these countries, vaccines are not mandatory. They all have similar processes with respect to process, standard of proof and elements of compensation. In Canada, only the province of Québec has a VIC Program, which has been running successfully since 1985. Concerns with VIC Programs include cost, difficulties assessing causality and concern that such programs may undermine public trust in vaccines; but these concerns can be addressed, especially in high-income countries that can bear the costs and have the capacity to manage the program.

Sexually transmitted infections (STIs) have historically been problematic for militaries. Recent reports indicating that rates of STIs among young male Canadian Armed Forces (CAF) members are higher than civilians prompted a need to better understand CAF members' reported rates of STIs and their behavioural risk factors for STIs. This study examined the prevalence of self-reported pre-military sexual behaviours (i.e. number of sexual partners and frequency of condom use) and history of a STI diagnosis among CAF recruits attending basic military training using data collected from the Recruit Health Questionnaire.

Data came from 50,603 recruits who participated in the survey between 2003 and 2018 (84.9% male, 78.6% Non-Commissioned Member candidates, 64.9% aged between 17 and 24 years).

Among sexually active recruits, the proportions who had more than one sexual partner in the previous year increased from 30.5% in 2003 (95% CI, 27.8-33.4) to 35.5% in 2018 (95% CI, 34.0-37.0). Of recruits who were not in an exclusive relationship at the time, the proportions who reported always using a condom decreased from 50.8% in 2003 (95% CI, 46.4-55.1) to 40.2% in 2018 (95% CI, 38.3-42.2). Overall, 5.5% (95% CI, 5.3-5.7) reported ever having received a STI diagnosis. Demographic differences by age and sex were also found.

These observations provide an indication of the baseline, pre-enlistment STI risk behaviours, and STI history among CAF recruits, and may provide insight into avenues for targeted interventions and health promotion programming, such as education and screening initiatives.

These observations provide an indication of the baseline, pre-enlistment STI risk behaviours, and STI history among CAF recruits, and may provide insight into avenues for targeted interventions and health promotion programming, such as education and screening initiatives.